Beauregard JM - Search Results

1

Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.

Hou X, Brosch J, Uribe C, Desy A, Böning G, Beauregard JM, Celler A, Rahmim A. Hou X, et al. Among authors: beauregard jm. J Nucl Med. 2021 Jul 1;62(7):1006-1011. doi: 10.2967/jnumed.120.254656. Epub 2020 Oct 30. J Nucl Med. 2021. PMID: 33127625 Free PMC article.

2

Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT.

Beauregard JM, Croteau E, Ahmed N, van Lier JE, Bénard F. Beauregard JM, et al. J Nucl Med. 2009 Jan;50(1):100-7. doi: 10.2967/jnumed.108.057000. Epub 2008 Dec 17. J Nucl Med. 2009. PMID: 19091905 Free article. Clinical Trial.

3

68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy.

Hofman MS, Beauregard JM, Barber TW, Neels OC, Eu P, Hicks RJ. Hofman MS, et al. Among authors: beauregard jm. J Nucl Med. 2011 Oct;52(10):1513-9. doi: 10.2967/jnumed.111.093344. Epub 2011 Sep 9. J Nucl Med. 2011. PMID: 21908388 Free article.

4

How we read FCH-PET/CT for prostate cancer.

Beauregard JM, Beaulieu A. Beauregard JM, et al. Cancer Imaging. 2016 Dec 6;16(1):41. doi: 10.1186/s40644-016-0101-5. Cancer Imaging. 2016. PMID: 27923396 Free PMC article.

5

Accuracy of ¹⁷⁷Lu activity quantification in SPECT imaging: a phantom study.

Uribe CF, Esquinas PL, Tanguay J, Gonzalez M, Gaudin E, Beauregard JM, Celler A. Uribe CF, et al. Among authors: beauregard jm. EJNMMI Phys. 2017 Dec;4(1):2. doi: 10.1186/s40658-016-0170-3. Epub 2017 Jan 7. EJNMMI Phys. 2017. PMID: 28063068 Free PMC article.

6

Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes.

Zhao W, Esquinas PL, Hou X, Uribe CF, Gonzalez M, Beauregard JM, Dewaraja YK, Celler A. Zhao W, et al. Among authors: beauregard jm. EJNMMI Phys. 2018 May 2;5(1):8. doi: 10.1186/s40658-018-0208-9. EJNMMI Phys. 2018. PMID: 29717385 Free PMC article.

7

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Arsenault F, Beauregard JM, Pouliot F. Arsenault F, et al. Among authors: beauregard jm. Curr Opin Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357. Curr Opin Support Palliat Care. 2018. PMID: 29939893 Review.

8

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized ¹⁷⁷Lu-octreotate PRRT.

Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM. Del Prete M, et al. Among authors: beauregard jm. EJNMMI Phys. 2018 Oct 15;5(1):25. doi: 10.1186/s40658-018-0224-9. EJNMMI Phys. 2018. PMID: 30318563 Free PMC article.

9

Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a ¹⁷⁷Lu-DOTATATE patient study.

Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A. Zhao W, et al. Among authors: beauregard jm. Phys Med Biol. 2019 Aug 28;64(17):175006. doi: 10.1088/1361-6560/ab3039. Phys Med Biol. 2019. PMID: 31287093

10

Personalized kidney dosimetry in ¹⁷⁷Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations.

Hou X, Zhao W, Beauregard JM, Celler A. Hou X, et al. Among authors: beauregard jm. Phys Med Biol. 2019 Aug 28;64(17):175004. doi: 10.1088/1361-6560/ab32a1. Phys Med Biol. 2019. PMID: 31456584

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters